![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}
Anas Younes, MD
Specialities: Waldenström's Macroglobulinemia, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma
Spoken languages: English
Clinical Expertise
- DLBCL Specialist
About
Prof. Younes has spent more than 25 years caring for patients with lymphoma and lead numerous clinical trials that advanced the field. His research resulted in the US Food and Drug Administration approval of two novel agents for patients with Hodgkin lymphoma, including the first targeted drug for the treatment of Hodgkin lymphoma in more than three decades (brentuximab vedotin), and the approval of the first immune checkpoint inhibitor for lymphoma (nivolumab).
Location
MD Anderson Cancer Center: 1515 Holcombe Blvd, Houston, TX 77030, USA
Get the latest thought leadership on your Waldenström's Macroglobulinemia delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.
HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.
Copyright © 2024 HealthTree Foundation. All rights reserved.
Tax ID 45-5354811